Skip to main content

All Articles

Liquid Biopsies Show High Correlation with Tissue Biopsy for Genetic Mutations

By Wayne Kuznar

July 2016, Vol 6, No 7

Summer Homework for Oncology: Successes and Failures in Oral Drugs Management

By Dawn Holcombe, MBA, FACMPE, ACHE

From the Editor

July 2016, Vol 6, No 7

Support Services Provide Some Relief from Financial Distress of Cancer Treatment, but More Is Needed

By Meg Barbor, MPH; Meg Barbor, MPH

July 2016, Vol 6, No 7

At the 2016 Community Oncology Alliance conference, Patricia J. Goldsmith, Chief Executive Officer of CancerCare, and Alan J. Balch, PhD, Chief Executive Officer of the Patient Advocate Foundation (PAF), discussed the services their organizations provide for patients, highlighting the cost barriers for patients with cancer. Read More ›

Integrating Survivorship Care in Oncology: A Conversation with Patricia Ganz, MD

Survivorship Care

July 2016, Vol 6, No 7

Select Ongoing Trials Currently Enrolling Patients with Leukemia

Clinical Trials Tracker

July 2016, Vol 6, No 7

Updated NCCN Multiple Myeloma Guideline Expands Patient Eligibility and Therapeutic Options

By Wayne Kuznar

NCCN Guideline Updates, Multiple Myeloma, Hematologic Malignancies, National Comprehensive Cancer Network (NCCN)

July 2016, Vol 6, No 7

Aggressive End-of-Life Care Still Offered to Younger, Non-Medicare Patients with Cancer

By Phoebe Starr

End-of-Life Care

July 2016, Vol 6, No 7

Atezolizumab Could Be Start of “Seismic Shift” in Metastatic Bladder Cancer Therapy

By Wayne Kuznar

July 2016, Vol 6, No 7

Alectinib May Be New First-Line Treatment for Patients with NSCLC and ALK Mutation

By Wayne Kuznar

July 2016, Vol 6, No 7

Three-Drug Regimen with Daratumumab a New Standard of Care for Relapsed or Refractory Multiple Myeloma

By Wayne Kuznar

Hematologic Malignancies, Multiple Myeloma

July 2016, Vol 6, No 7

Page 246 of 299